Skip to content
Clinical Trials – home
FinlandBack to Finland

Clinical trials in Jarvenpaa

403 clinical trials in Jarvenpaa, Finland. Every trial is listed in the EU Clinical Trials Register and updated daily.

FinlandOur site in FinlandKliinisetTutkimukset.fi(opens in a new tab)
Jarvenpaa at a glance
403
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

403 trials in Jarvenpaa

Open in trial search

Bronchiectasis

Recruiting

Study of BI 1291583 tablets taken once daily for 76 weeks in adults with bronchiectasis

Investigational
Countries:FinlandFinland
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:BI 1291583
  • Sponsor:Boehringer Ingelheim Espana S.A.

Phase 2b Study of VXB-221 and VXB-213 Protein Vaccine for Prevention of Respiratory Syncytial Virus and Human Metapneumovirus Infections in Adults ≥60 Years

Investigational
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:VXB-213
  • Sponsor:Sanofi Pasteur Inc.

Cardiac failure

Recruiting

Study of maridebart cafraglutide for patients with heart failure with preserved or mildly reduced ejection fraction and obesity

Investigational
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Maridebart Cafraglutide
  • Sponsor:Amgen Inc.

Obesity+1

Recruiting

Phase 3 Extension Trial Evaluating Long‑Term Efficacy, Safety and Tolerability of maridebart cafraglutide in Adults with Obesity

Investigational
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Maridebart Cafraglutide
  • Sponsor:Amgen Inc.

Randomized Phase III trial of elecoglipron plus dapagliflozin on kidney outcomes and mortality in adults with chronic kidney disease

Registered drug
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:AZD5004
  • Sponsor:AstraZeneca AB

Contraception+1

Recruiting

Contraceptive efficacy, safety and tolerability of drospirenone 4 mg (LPRI‑CF113) in healthy women of reproductive age over 13 cycles

InvestigationalNo placebo
Countries:FinlandFinland
  • Participants:0–17 years · 18–64 years · Healthy volunteers
  • Substances:Drospirenone
  • Sponsor:Chemo Research S.L.

Narcolepsy

Recruiting

Efficacy and Safety of ALKS 2680 and Alixorexton in Adults with Narcolepsy Type 1

Investigational
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:ALKS 2680
  • Sponsor:Alkermes Inc.

Narcolepsy

Recruiting

Phase 3 Randomized Study of ALKS 2680 for Excessive Daytime Sleepiness in Adults with Narcolepsy Type 1

Investigational
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:ALKS 2680
  • Sponsor:Alkermes Inc.

Phase 2a Study of Safety, Tolerability and Efficacy of Intranasal Cenegermin in Adults with Moderate to Severe Subacute Traumatic Brain Injury

Investigational
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Cenegermin
  • Sponsor:Dompe' Farmaceutici S.p.A.

COVID-19

Recruiting

A study testing molnupiravir in adults with COVID-19 who are not hospitalized and are at high risk for serious illness

Investigational
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Molnupiravir
  • Sponsor:Merck Sharp & Dohme LLC

Study of vicadrostat and empagliflozin combination in patients with type 2 diabetes, high blood pressure and cardiovascular disease

Registered drug
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:BI 690517
  • Sponsor:Boehringer Ingelheim Espana S.A.

Study of GSK5764227 alone and in combination for patients with previously treated advanced gastrointestinal tumors that cannot be removed by surgery or have spread

InvestigationalNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:GSK5764227
  • Sponsor:Glaxosmithkline Research & Development Limited

Other cities in Finland

The busiest research cities in the country

All 28 cities in Finland

Clinical research in Jarvenpaa

What the registry says about research in the country

01 Respiratory Virus Prevention

Innovative research focusing on respiratory syncytial virus (RSV) and influenza vaccines, evaluating new preventive approaches for both young and elderly populations.

  • RSV vaccine development for seniors
  • Influenza vaccine efficacy studies
  • Combined viral protection research

Multiple clinical trials are exploring breakthrough vaccine technologies, including mRNA platforms.

02 Meningococcal Disease Research

Comprehensive studies on meningococcal vaccines targeting multiple disease strains, with particular focus on protecting infants and young children.

  • Pentavalent vaccine development
  • Long-term immunity studies
  • Pediatric vaccination protocols

Research aims to enhance protection against various meningococcal serogroups through innovative conjugate vaccines.

03 Viral Disease Prevention

Advanced research into preventing cytomegalovirus and herpes zoster infections, utilizing cutting-edge vaccine technologies.

  • CMV prevention strategies
  • Herpes zoster vaccine efficacy
  • Pneumococcal protection studies

These trials focus on developing robust immune responses in specific target populations.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.